 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stelis and Syngene have executed the final agreements to transfer its Unit 3 multi-modal facility in Bengaluru to Syngene with gross consideration adjusted from Rs 702 crore to Rs 617 crore.

Strides Pharma gains on transfer of Bengaluru facility to Syngene

The company's wholly owned step-down subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval.

Strides Pharma rallies after seizure drug receives US FDA approval

Strides Pharma Consolidated September 2023 Net Sales at Rs 999.43 crore, up 11.41% Y-o-Y

Strides Pharma Standalone September 2023 Net Sales at Rs 540.29 crore, up 12.27% Y-o-Y

The drug firm had reported a net profit of Rs 19 crore for the year-ago period.

Strides Pharma Science Q2 loss at Rs 149 crore

Additionally, as part of the transaction, Rxilient Biohub will assume the long-term lease obligation associated with the manufacturing site from Strides

Strides Pharma to sell its Singapore manufacturing facility for $15 million

The company has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the United States Food &amp; Drug Administration (USFDA).

Strides Pharma Science trades marginally lower despite USFDA nod

ICICI Securities recommended reduce rating on Strides Pharma Science with a target price of Rs 495 in its research report dated September 26, 2023.

Reduce Strides Pharma Science; target of Rs 495: ICICI Securities

Sharekhan recommended Hold rating on Strides Pharma Science with a target price of Rs 600 in its research report dated September 26, 2023.

Hold Strides Pharma Science; target of Rs 600: Sharekhan

Demerger will be completed by April 1, 2024 according to the stock exchange filing

Strides Pharma to spin off CDMO, soft gelatin biz into OneSource; listing expected in 12 months

Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. It operates through the Pharmaceutical and Bio-pharmaceutical business segments. The company was founded by Arun N. Kumar on June 28, 1990 and is headquartered in Bangalore, India.

Market Cap	43.92B
Volume (M)	1.45M
52-Wk High	549.00
52-Wk Low	268.15

STAR.NSE Strides Pharma Science Ltd.

About

Feed

News

Fundamentals